Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)

• Status: Completed
• Trial end date: 2016-10-22
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the study is to observe the effect of adherence to once-daily administered long-acting bronchodilators (long-acting ß2-agonists [LABAs] / long-acting muscarinic antagonists [LAMAs]) on patients health related quality of life (HR-QoL) and to assess the relation between symptoms improvement and adherence to Chronic Obstructive Pulmonary Disease (COPD) maintenance therapy

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Bromides; Tiotropium Bromide

Criteria

Inclusion criteria:

1. Male or female, above 40 years of age

2. Patients clinically diagnosed of COPD with no history suggestive of asthma:

1. by scores >=5 in the COPD Population Screener,

2. by a clinical diagnosis of COPD made by pulmonologists or internists,

3. by a Forced Expiratory Volume (FEV1)/ Forced Vital Capacity (FVC6) ratio of <=0.70 and a FEV1 <=80% of the predicted value as assessed by copd-6 (Vitalograph, UK);

3. Maintenance treatment-naïve COPD patients who have been prescribed once daily long-acting bronchodilators (LABAs / LAMAs) for the first time at enrolment into the study

4. Patients who are able to provide signed informed consent

5. Patients who agree to be contacted for telephone/ SMS reminders via call center

Exclusion criteria:

1. Patients with contraindications to the prescribed medication

2. Patients with any disorder that would prevent the patient from being able to complete questionnaires either verbally or by self-completion

3. Pregnant or lactating women or women of childbearing potential not using an acceptable method of contraception